Hill G M, Brewer G J, Juni J E, Prasad A S, Dick R D
Am J Med Sci. 1986 Dec;292(6):344-9. doi: 10.1097/00000441-198612000-00002.
The efficacy of zinc as a therapeutic agent to control copper balance in Wilson's disease patients has been previously documented with balance studies. In an attempt to develop a simpler and faster tool for evaluating the adequacy of zinc therapy, a technique that measures the uptake into blood of a small oral dose of 64copper was studied in conjunction with copper balance. The mean peak 64copper uptake into blood of nine Wilson's disease patients on D-penicillamine, trien, or no medication was 6.04 +/- 2.74%, comparable with normal controls. Seven patients on zinc therapy had a markedly and significantly reduced mean uptake of 0.79 +/- 1.05% after treatment. The data demonstrate that the prevention of copper uptake into blood in Wilson's disease patients by zinc therapy can be evaluated by 64copper uptake and that peak uptakes of less than 1% occur in patients with neutral or negative copper balance.
锌作为一种治疗剂来控制威尔逊氏病患者铜平衡的疗效，此前已通过平衡研究得到证实。为了开发一种更简单、更快的工具来评估锌治疗的充分性，研究了一种测量口服小剂量64铜进入血液摄取量的技术，并结合铜平衡进行研究。9名接受青霉胺、曲恩治疗或未接受药物治疗的威尔逊氏病患者血液中64铜摄取量的平均峰值为6.04±2.74%，与正常对照组相当。7名接受锌治疗的患者在治疗后平均摄取量显著降低，为0.79±1.05%。数据表明，通过64铜摄取可以评估锌治疗对威尔逊氏病患者血液中铜摄取的预防作用，并且在铜平衡为中性或负性的患者中，峰值摄取量低于1%。
